Wedbush Morgan upgrades Salix Pharmaceuticals (Nasdaq: SLXP) from Relative Underperform to Outperform. Price target increases from $10 to $25.

Wedbush ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE